Teva Pharmaceuticals USA, Inc recalls
13 recall notices naming Teva Pharmaceuticals USA, Inc since January 2025, in United States. The most recent was published 21 Oct 2026.
13recalls on record
Latest recalls (13)
- FDATeva Pharmaceuticals USA, Inc recalls Metoclopramide TabletsFDAPresence of Foreign Tablets/Capsules
- FDATeva Pharmaceuticals USA, Inc recalls traZODone Hydrochloride TabletsFDAPresence of Foreign Tablets/Capsules
- FDATeva Pharmaceuticals USA, Inc recalls Octreotide Acetate for Injectable SuspensionFDALack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the…
- FDATeva Pharmaceuticals USA, Inc recalls Claravis (isotretinoin capsuleFDAFailed Impurities/Degradation Specifications: Out of specification for specific impurity Tretinoin
- FDATeva Pharmaceuticals USA, Inc recalls Isotretinoin CapsulesFDASuperpotent and Subpotent
- FDATeva Pharmaceuticals USA, Inc recalls Clonidine Transdermal SystemFDACGMP Deviations: use of an unapproved raw material
- FDATeva Pharmaceuticals USA, Inc recalls Octreotide Acetate for Injectable SuspensionFDALack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the…
- FDATeva Pharmaceuticals USA, Inc recalls Metoprolol Succinate Extended-Release TabletsFDAFailed Dissolution Specifications
- FDATeva Pharmaceuticals USA, Inc recalls Carton labelFDADefective Container - A defect in the side-seal which allows leakage of product.
- FDATeva Pharmaceuticals USA, Inc recalls Amoxicillin and Clavulanate Potassium for Oral Suspension USPFDASubpotent drug; Clavulanate Potassium component
- FDATeva Pharmaceuticals USA, Inc recalls Prazosin HydrochlorideFDACGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable…
- FDATeva Pharmaceuticals USA, Inc recalls Metoclopramide TabletsFDAPresence of foreign tablets/capsules.
- FDATeva Pharmaceuticals USA, Inc recalls Granix (tbo-filgrastim) Injection 300 mcg/0.5 mLFDAFailed Stability Specifications - 12-month stability test result for one of the known peptides is below the specification limit